Vous avez cherché: cf (Anglais - Croate)

cf comment
komentar

non-cf bronchiectasis
bronhiektazije nepovezane s cističnom fibrozom

cohesion fund (cf)
kohezijski fond (kf)

cf related diabetes
dijabetes povezan s cističnom fibrozom

(cf) annex iiiix
(cn) prilog iiiix.

buenos aires (ba, cf)
buenos aires (ba, cf)

e-cohesion for erdf, esf, cf
e-kohezija za efrr, esf, kf

audit methods for erdf, esf, cf
metode revizije za efrr, esf, kf

decreased appetite cf related diabetes dehydration1
smanjen apetit dijabetes povezan s cističnom fibrozom dehidracija1

connecting europe facility (cef) – cf contribution
instrument za povezivanje europe (cef) – doprinos kohezijskog fonda

with cf who have a specified cftr gating mutation and are aged 2 through 5
cističnom fibrozom, koja imaju utvrđenu mutaciju gena cftr zbog koje dolazi

ecorn cf: european centres of reference network for cystic fibrosis
ecorn cf: europska mreža referentnih centara za cističnu fibrozu

efficacy and safety have not been established in non-cf bronchiectasis patients.
sigurnost i djelotvornost lijeka nisu utvrđene u pacijenata s bronhiektazijama nepovezanim s cističnom fibrozom.

elevated transaminases have been reported in patients with cf receiving lumacaftor/ivacaftor.
povišene vrijednosti transaminaza zabilježene su u bolesnika s cističnom fibrozom koji primaju lumakaftor/ivakaftor.

col 3:10 ) and hearts ( cf . rom 10:8 ) .
kol 3, 10 ) i vašim srcima ( usp .

abnormalities in liver function, including advanced liver disease, can be present in patients with cf.
u bolesnika s cističnom fibrozom mogu biti prisutni poremećaji funkcije jetre, uključujući uznapredovalu bolest jetre.

disaggregated by purpose of travel (cf; field 21 of the application form set out in annex i
raščlanjen po svrsi/svrhama putovanja (vidi rubriku 21 obrasca zahtjeva iz priloga i.)

a single sputum sample from a cf patient may contain multiple isolates of p. aeruginosa and each isolate may have a different level of in vitro susceptibility to aztreonam.
jedan uzorak iskašljaja bolesnika s cf-om može sadržavati više izolata p. aeruginosa, a svaki od njih može imati različitu razinu osjetljivosti na aztreonam in vitro.

available data from studies dpm-cf-301 and 302 suggest that no dose adjustments are required for these patient populations.
dostupni podaci ispitivanja dpm-cf-301 i 302 pokazuju da za te populacije pacijenata nije potrebno izvršiti prilagodbu doze.

assessment of adverse reactions is based on experience in four phase 3 clinical studies involving cf patients with chronic p. aeruginosa infection and post-marketing spontaneous reporting.
procjena nuspojava temelji se na iskustvu iz četiri klinička ispitivanja faze 3 koja su uključivala cf bolesnike s kroničnom infekcijom p. aeruginosa i spontane prijave nakon stavljanja lijeka u promet.